Literature DB >> 20491

Vehicle effects on ocular drug bioavailability II: Evaluation of pilocarpine.

J W Sieg, J R Robinson.   

Abstract

The influence of vehicle composition on ocular penetration of pilocarpine was studied in the albino rabbit. Increasing the pH of a vehicle promoted increased corneal penetration for pilocarpine, in accordance with the pH-partition hypothesis, but a similar series of experiments with a nonionizable drug, glycerin, gave similar results. The extent of pH-induced lacrimation by the vehicle and its effect on precorneal drug concentration also was determined. Increased pilocarpine absorption at neutral to slightly alkaline pH was due primarily to its peculiar solubility characteristics coupled with less irritation and lacrimation rather than a direct pH effect on the molecule. Incorporation of pilocarpine into a petrolatum-based ointment vehicle resulted in increased aqueous humor pilocarpine levels above those provided by an equivalent dose of aqueous solution. The mechanism of this increase was determined to be a higher effective concentration of pilocarpine in the ointment vehicle coupled with an increase in contact time of the dose. The ointment system also exerted an unusual form of vehicle control in that it promoted the corneal penetration of pilocarpine while impeding uniform mixing of the dose with tears and thereby imposed a restriction on the amount of pilocarpine available to the ocular tissues.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 20491     DOI: 10.1002/jps.2600660905

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.

Authors:  Feng Deng; Veli-Pekka Ranta; Heidi Kidron; Arto Urtti
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

2.  Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: a comparison with corneal penetration.

Authors:  P Ashton; S K Podder; V H Lee
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

3.  Formulation, in vitro dissolution, and ocular bioavailability of high- and low-melting phenylephrine oxazolidines.

Authors:  Y Qiu; J K Guillory; R D Schoenwald
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

4.  The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine.

Authors:  J J Hagan; B van der Heijden; C L Broekkamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

5.  Piloplex, a new long-acting pilocarpine polymer salt. A: Long-term study.

Authors:  U Ticho; M Blementhal; S Zonis; A Gal; I Blank; Z W Mazor
Journal:  Br J Ophthalmol       Date:  1979-01       Impact factor: 4.638

6.  Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Authors:  Hussein O Ammar; H A Salama; M Ghorab; A A Mahmoud
Journal:  AAPS PharmSciTech       Date:  2009-06-18       Impact factor: 3.246

7.  Ocular and systemic bioavailability of ophthalmic flurbiprofen.

Authors:  D D Tang-Liu; S S Liu; R J Weinkam
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

8.  Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response.

Authors:  SivaNaga S Anumolu; Yashveer Singh; Dayuan Gao; Stanley Stein; Patrick J Sinko
Journal:  J Control Release       Date:  2009-03-31       Impact factor: 9.776

9.  Prolonged pulse-entry of pilocarpine with a soluble drug insert.

Authors:  L Salminen; A Urtti; H Kujari; M Juslin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

10.  Partitioning and Spatial Distribution of Drugs in Ocular Surface Tissues.

Authors:  Anusha Balla; Seppo Auriola; Angus C Grey; Nicholas J Demarais; Annika Valtari; Emma M Heikkinen; Elisa Toropainen; Arto Urtti; Kati-Sisko Vellonen; Marika Ruponen
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.